Skip to main content
Glama

pulsenetwork

by com.theaslangroupllc.pulse
OverviewDiscussionsAdmin

clinicalintelpulse

ClinicalIntelPulse: Pharmaceutical pipeline and clinical trial intelligence API. Synthesizes 400,000+ registered trials from ClinicalTrials.gov with FDA OpenFDA, PubMed, and real-time news. All endpoints require x402 pay

Coverage: Global

Endpoints: • trial-check ($0.02): ClinicalTrials.gov lookup — single trial by NCT id or filtered search, deterministic • pipeline-scan ($0.15): Phase 2/3 pipeline scan • approval-outlook ($0.25): FDA/EMA approval probability • sponsor-intel ($0.20): Pharma/biotech pipeline intelligence • disease-landscape ($0.35): Full disease landscape report • trial-brief ($0.10): Clinical trial deep dive by NCT ID • mechanism-map ($0.20): Drug target and MOA landscape • global-trials ($0.15): Global clinical trial landscape • failure-analysis ($0.20): Clinical trial failure analysis • patient-finder ($0.10): Recruiting trial finder (plain language) • deal-signal ($0.35): Biotech M&A and licensing deal signals • drug-check ($0.10): What is this medication? (plain language) • interaction-check ($0.15): Can these medications be taken together? • recall-check ($0.10): Is my medication recalled? • disease-landscape-lite ($0.25): Disease landscape — $0.25 deterministic preview • deal-signal-lite ($0.25): Deal signal — $0.25 deterministic preview

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
nctNoSingle trial by NCT id, e.g. NCT02142738
drugNoBrand or generic medication name — e.g. 'Ozempic' | 'metformin' | 'ibuprofen'
langNoResponse language
depthNodepth
drugsNoTwo to eight medication names, comma-separated — e.g. 'warfarin,ibuprofen'
focusNofocus
limitNo1-25, default 10
phaseNo1|2|3|4
stageNostage
actionYesWhich endpoint to call. Options: trial-check | pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check | disease-landscape-lite | deal-signal-lite
agencyNoagency
nct_idNoNCT identifier — e.g. NCT04368728
regionNoregion
statusNoRECRUITING | COMPLETED | ...
countryNoOptional country filter — e.g. 'United States' | 'Germany' | 'Australia'
horizonNohorizon
sponsorNoSearch by sponsor
conditionNoSearch by condition
deal_typeNodeal_type
mechanismNoOptional focus — e.g. 'BTK inhibitor' | 'CAR-T' | 'IL-17'

Schema Changelog

Changes observed during successful MCP inspections.

  1. Changed2 schema fields changed
    • changedInput schema / properties / action / description
      Previous value: -"Which endpoint to call. Options: trial-check | pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check"New value: +"Which endpoint to call. Options: trial-check | pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check | disease-landscape-lite | deal-signal-lite"
    • changedInput schema / properties / action / enum
      Previous value: -[
-  "trial-check",
-  "pipeline-scan",
-  "approval-outlook",
-  "sponsor-intel",
-  "disease-landscape",
-  "trial-brief",
-  "mechanism-map",
-  "global-trials",
-  "failure-analysis",
-  "patient-finder",
-  "deal-signal",
-  "drug-check",
-  "interaction-check",
-  "recall-check"
-]New value: +[
+  "trial-check",
+  "pipeline-scan",
+  "approval-outlook",
+  "sponsor-intel",
+  "disease-landscape",
+  "trial-brief",
+  "mechanism-map",
+  "global-trials",
+  "failure-analysis",
+  "patient-finder",
+  "deal-signal",
+  "drug-check",
+  "interaction-check",
+  "recall-check",
+  "disease-landscape-lite",
+  "deal-signal-lite"
+]
  2. Changed8 schema fields changed
    • changedInput schema / properties / action / description
      Previous value: -"Which endpoint to call. Options: pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check"New value: +"Which endpoint to call. Options: trial-check | pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check"
    • changedInput schema / properties / action / enum
      Previous value: -[
-  "pipeline-scan",
-  "approval-outlook",
-  "sponsor-intel",
-  "disease-landscape",
-  "trial-brief",
-  "mechanism-map",
-  "global-trials",
-  "failure-analysis",
-  "patient-finder",
-  "deal-signal",
-  "drug-check",
-  "interaction-check",
-  "recall-check"
-]New value: +[
+  "trial-check",
+  "pipeline-scan",
+  "approval-outlook",
+  "sponsor-intel",
+  "disease-landscape",
+  "trial-brief",
+  "mechanism-map",
+  "global-trials",
+  "failure-analysis",
+  "patient-finder",
+  "deal-signal",
+  "drug-check",
+  "interaction-check",
+  "recall-check"
+]
    • changedInput schema / properties / condition / description
      Previous value: -"Disease or condition — e.g. 'Non-Small Cell Lung Cancer' | 'Alzheimer Disease' | 'Type 2 Diabetes'"New value: +"Search by condition"
    • addedInput schema / properties / limit
      Added value: +{
+  "description": "1-25, default 10",
+  "type": "string"
+}
    • addedInput schema / properties / nct
      Added value: +{
+  "description": "Single trial by NCT id, e.g. NCT02142738",
+  "type": "string"
+}
    • changedInput schema / properties / phase / description
      Previous value: -"phase"New value: +"1|2|3|4"
    • changedInput schema / properties / sponsor / description
      Previous value: -"Company name — e.g. 'Moderna' | 'Alnylam' | 'Vertex Pharmaceuticals'"New value: +"Search by sponsor"
    • changedInput schema / properties / status / description
      Previous value: -"status"New value: +"RECRUITING | COMPLETED | ..."
  3. Changed4 schema fields changed
    • changedInput schema / properties / action / description
      Previous value: -"Which endpoint to call. Options: pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal"New value: +"Which endpoint to call. Options: pipeline-scan | approval-outlook | sponsor-intel | disease-landscape | trial-brief | mechanism-map | global-trials | failure-analysis | patient-finder | deal-signal | drug-check | interaction-check | recall-check"
    • changedInput schema / properties / action / enum
      Previous value: -[
-  "pipeline-scan",
-  "approval-outlook",
-  "sponsor-intel",
-  "disease-landscape",
-  "trial-brief",
-  "mechanism-map",
-  "global-trials",
-  "failure-analysis",
-  "patient-finder",
-  "deal-signal"
-]New value: +[
+  "pipeline-scan",
+  "approval-outlook",
+  "sponsor-intel",
+  "disease-landscape",
+  "trial-brief",
+  "mechanism-map",
+  "global-trials",
+  "failure-analysis",
+  "patient-finder",
+  "deal-signal",
+  "drug-check",
+  "interaction-check",
+  "recall-check"
+]
    • addedInput schema / properties / drug
      Added value: +{
+  "description": "Brand or generic medication name — e.g. 'Ozempic' | 'metformin' | 'ibuprofen'",
+  "type": "string"
+}
    • addedInput schema / properties / drugs
      Added value: +{
+  "description": "Two to eight medication names, comma-separated — e.g. 'warfarin,ibuprofen'",
+  "type": "string"
+}
  4. First observed

TDQS

A3.5/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

With no annotations provided, the description carries the full burden. It discloses the x402 payment requirement and notes 'deterministic' behavior for trial-check and lite endpoints, and mentions data sources. However, it does not explain response formats, rate limits, error handling, or whether operations are read-only. This adds useful context but leaves significant behavioral traits undocumented.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is well-structured: a one-sentence summary, 'Coverage: Global,' then a bulleted endpoint list. It is front-loaded with the main purpose and uses a consistent format. While long, each endpoint entry earns its place by clarifying the action options. Minor redundancy exists with repeated determinism notes, but overall it is efficient and scannable.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness2/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with 20 parameters, 16 endpoints, no output schema, and no annotations, this description is incomplete. It does not map which parameters apply to which endpoint, explain response formats, or state which arguments are required for each action. An agent would struggle to correctly invoke most endpoints without additional inference, making the description insufficient for the tool's complexity.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Although schema description coverage is 100%, most parameter descriptions are tautological (e.g., 'depth', 'focus'). The description compensates by explaining the `action` enum: each endpoint is described with its price and purpose (e.g., 'trial-check ($0.02): ClinicalTrials.gov lookup — single trial by NCT id or filtered search'). This adds real meaning for the central parameter, though other parameters like `horizon` and `deal_type` remain unclear.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with 'ClinicalIntelPulse: Pharmaceutical pipeline and clinical trial intelligence API,' which clearly states the tool's domain and function. It further specifies data sources (ClinicalTrials.gov, FDA OpenFDA, PubMed, news) and lists 16 distinct endpoints, making it unambiguous what the tool does and distinguishing it from siblings like airdroppulse or alphapulse.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines2/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides no guidance on when to use this tool versus alternatives. It lists endpoints and prices but does not specify ideal use cases, prerequisites, or exclusions. The only usage constraint is 'All endpoints require x402 pay,' which is a payment requirement, not a usage guideline.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All pulsenetwork toolsInspect
Try in Browser
One endpoint for every MCP toolRayrun runs every MCP server behind one URL and holds the credentials. Each call is decided per client, tool, and argument, then recorded.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

Resources